Table 2.
The implications of ERO1α in tumors
| Cancer type | Ref. | Biological behavior | EMT | Angiogenesis | Xenograft in mice | Prognostic significance (Patients with ERO1A +/high) |
|---|---|---|---|---|---|---|
| Breast cancer | [93] | - | - | - | - | RFS↓ |
| [87] | - | - | CD31(KD↓, OE↑), HUVEC(OE↑) | Lung metastasis (KD↓), OS (KD↓) | - | |
| [70] | KD(NS) | - | - | Tumor growth (KD↓, OE↑), OS (KD↑, OE↓) | - | |
| [94] | - | - | CD31 (KD↓, OE↑) | Tumor growth (KD↓, OE↑) | OS↓, # | |
| [95] | - | - | Tumor growth (KD↓), lung metastasis (KD↓) | DFS↓, OS↓, # | ||
| [96] | KO↓ | - | HUVEC (KO↓) | Tumor growth (KO NS), lung metastasis (KO↓) | OS (NS) | |
| Lung cancer | [97] | - | - | - | - | RFS↓ |
| [64] | - | - | - | - | RFS↓, OS↓, DFS↓ | |
| [65] | KD↓, OE↑ | KD↓, OE↑ | - | Tumor metastasis (KD↓, OE↑) | RFS↓, OS↓ | |
| [67] | KD↓ | - | - | - | OS↓ | |
| [66] | KD↓, OE↑ | - | - | Tumor growth (KO↓) | - | |
| [68] | - | - | - | - | DFS↓, # | |
| Bile duct cancer | [63] | KD↓, OE↑ | KD↓, OE↑ | - | - | DFS (NS), OS↓, # |
| Prostate cancer | [71] | KD↓ | - | - | - | - |
| Pancreatic cancer | [99] | KD↓ | - | - | Tumor growth (EN460↓), | OS↓, DFS ↓ |
| liver metastasis (EN460↓), OS (EN460↓) | ||||||
| [69] | KD↓, OE↑ | - | - | Tumor growth (KD↓, OE↑) | - | |
| [68] | KD↓, OE↑ | - | - | Tumor growth (KD↓, OE↑) | OS↓, # | |
| Gastric cancer | [100] | KD↓ | - | - | - | RFS↓, OS↓ |
| Colon cancer | [101] | KD (NS) | KO↓ | - | Tumor growth (KO↓) | - |
| Liver cancer | [58] | KD↓, OE↑ | KD↓, OE↑ | HUVEC (KD↓, OE↑), CD34 (KD↓, OE↑) | Lung metastasis (KD↓, OE↑) | RFS↓, OS↓ |
| Cervical cancer | [63] | KO↓ | KO↓ | - | Tumor growth (KO↓) | OS↓ |
Duplicate data in different references was deleted and only one was retained. EMT, epithelial–mesenchymal transition; NS, no significance; KD, knockdown; KO, knockout; OE, overexpression; EN460, ERO1α inhibitor; HUVEC, human umbilical vein endothelial cells; OS, overall survival; RFS, recurrence-free survival; DFS, disease-free survival; #, Independent prognostic factor; -, none.